Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007 in patients with moderate-to-severe atopic dermatitis Topline data expected in the fourth quarter of 2026 SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene”), a clinical-stage biotechnology company dedicated to developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced […]